TwinBeech Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

TwinBeech Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-97,333	Closed	-$7.76M	–	872
2022 Q2	$7.76M	Buy	97,333 +53,933	+124%	+$5.11M	0.35%	84
2022 Q1	$4.57M	Buy	43,400 +29,979	+223%	+$2.92M	0.2%	137
2021 Q4	$1.45M	Buy	+13,421	New	+$1.46M	0.08%	279
2021 Q1	–	Sell	-47,383	Closed	-$3.47M	–	727
2020 Q4	$3.47M	Buy	47,383 +41,983	+777%	+$3.12M	0.56%	44
2020 Q3	$419K	Buy	+5,400	New	+$372K	0.09%	297
2020 Q2	–	Sell	-25,488	Closed	-$755K	–	532
2020 Q1	$755K	Buy	+25,488	New	+$862K	0.3%	120

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

TwinBeech Capital's HZNP Position: Q3 2022 in Review

TwinBeech Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 97,333 shares — an estimated $7.76M sold.

TwinBeech Capital first reported a position in HZNP in Q1 2020 and held it in 6 quarters. The position peaked at $7.76M in Q2 2022. 529 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

TwinBeech Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
TwinBeech Capital sold 97,333 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $7.76M.
TwinBeech Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2020 and held it in 6 quarters.
TwinBeech Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7.76M in Q2 2022.
529 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on TwinBeech Capital's 13F filing for Q3 2022, filed 14 Nov 2022.